President Obama is asking for more than $1 billion in new funding to address the opioid epidemic, USA Today reports. The funding would expand access to treatment for prescription drug abuse and heroin use.
Under the proposal, the new funds would be used to help people with an opioid use disorder to seek and successfully complete treatment and sustain recovery. It would expand access to substance use treatment providers and to medication-assisted treatment for opioid use disorders.
The funds will be included in the fiscal year 2017 budget request, the article notes. They include $920 million to support agreements with states to expand access to medication-assisted treatment for opioid use disorders. States can use these funds to expand treatment and lower the cost of services.
Fifty million dollars would be used to expand access to 700 substance use treatment providers in areas that need mental health treatment the most, while $30 million would be used to evaluate the effectiveness of treatment programs using medication-assisted treatment. Those funds would also help identify opportunities to improve treatment for patients with opioid use disorders.
The proposal also includes about $500 million to build on current efforts by the Departments of Justice and Health and Human Services to expand state-level prescription drug overdose prevention strategies. These funds would increase the availability of medication-assisted treatment programs, improve access to the opioid overdose antidote naloxone, and support targeted enforcement activities.
In a statement, the White House said the proposal “will not only expand access to help people start treatment, but help them successfully complete it and sustain their recovery. It will increase education, prevention, drug monitoring programs, and law enforcement efforts to keep illegal drugs out of our communities.”
The FDA recently voted in favor of pushing a new formulation of oxycodone hydrochloride for approval. The new OxyContin formula is more difficult to crush or dissolve which will hopefully make it harder to be used as a drug of abuse . The FDA recommended that Purdue Pharma's application for a new, resin-coated formulation should replace the original version, which has been on the market since 1996. Randall Flick, MD, an anesthesiologist at the Mayo Clinic who voted to recommend approval of the drug said, "Clearly the old formulation is worse than the new, although I think the difference is relatively small," Flick concluded, "Hardcore abusers are likely to devise new ways to break down the harder tablet or figure out which solvents will dissolve it fastest, within 'day or weeks' of the product's release on the market."